NCT05630352View on ClinicalTrials.gov

A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 6, 2025

Primary Completion Date

July 13, 2026

Study Completion Date

July 13, 2026

Conditions
COVID-19
Interventions
BIOLOGICAL

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose

Injection in the muscle

BIOLOGICAL

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose

Injection in the muscle

BIOLOGICAL

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose

Injection in the muscle

BIOLOGICAL

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose

Injection in the muscle

Sponsors

Lead Sponsor

BioNTech SE

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

BioNTech SE

INDUSTRY